Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00766025
Recruitment Status : Completed
First Posted : October 3, 2008
Last Update Posted : March 2, 2009
Information provided by:

Brief Summary:
The main purpose of this study is to examine Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers while taking single and multiple dosing a rosuvastatin calcium.

Condition or disease Intervention/treatment Phase
CYP2C19 Poor Extensive Metabolizers Drug: Rosuvastatin Calcium Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium
Study Start Date : September 2008
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Rosuvastatin Calcium Drug: Rosuvastatin Calcium
single oral dose on days 1, 4, 5, 6, 10-16, 17

Primary Outcome Measures :
  1. Blood levels of rosuvastatin in Taiwanese subjects identified as CYP2CIP poor and extensive metabolizers [ Time Frame: Scheduled times during the 18 days that the study drug is taken ]
  2. Blood levels for assessment of pharmacodynamic (lipid) parameters [ Time Frame: Days -1 and 18 ]

Secondary Outcome Measures :
  1. Safety and tolerability of rosuvastatin in Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers [ Time Frame: Screening through completion of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject must have blood drawn for genotyping (determination of EM or PM of CYP2C19, determination of OATP-C1B1, BCRP 421C>A, and CYP2C9.
  • Males and females aged 20-65, inclusive
  • Women who are surgically sterilized, post-menopausal for at least one year, or not pregnant and/or lactating. Women of childbearing potential must be willing to abstain from sexual activity or use an effective contraception as outlined in protocol.

Exclusion Criteria:

  • Subjects with deoxyribonucleic acid (DNA) that codes for OATP-C 1B1 *5 and *15, BCRP 421C>A and/or non wild-type CYP2C9
  • History of adverse drug reaction or hypersensitivity to statins or drugs with a similar chemical structure to rosuvastatin
  • History or presence of gastrointestinal, hepatic, or renal disease or other conditions known to interfere with absorption, distribution, metabolism and excretion (ADME) of drugs
  • Any contraindication determined by review of a detailed medical and drug history, complete physical examination, vital signs, blood chemistry, hematology, and electrocardiogram (ECG)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00766025

Research Site
Taipei, Taiwan
Sponsors and Collaborators
Study Director: Regeio Mosquea-Garcia, MD AstraZeneca
Study Director: Robin Meng, MD, PhD AstraZeneca
Principal Investigator: Tzung-Dau Wang, MD Northern Taiwan University Hospital

Responsible Party: Michael Cressman, Medical Science Executive Director, Clinical Development, Cardiovascular, AstraZeneca Pharmaceuticals Identifier: NCT00766025     History of Changes
Other Study ID Numbers: D3560C00059
Rosuvastatin Calcium
First Posted: October 3, 2008    Key Record Dates
Last Update Posted: March 2, 2009
Last Verified: February 2009

Keywords provided by AstraZeneca:
Taiwanese Subjects
Poor Metabolizers
Extensive Metabolizers
Taiwanese Subjects identified as CYP2C19 Poor or Extensive Metabolizers

Additional relevant MeSH terms:
Calcium, Dietary
Rosuvastatin Calcium
Bone Density Conservation Agents
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors